Myriad Genetics (MYGN) Cash & Current Investments: 2009-2025
Historic Cash & Current Investments for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to $145.4 million.
- Myriad Genetics' Cash & Current Investments rose 45.55% to $145.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $414.0 million, marking a year-over-year decrease of 6.42%. This contributed to the annual value of $102.4 million for FY2024, which is 27.32% down from last year.
- Latest data reveals that Myriad Genetics reported Cash & Current Investments of $145.4 million as of Q3 2025, which was up 95.43% from $74.4 million recorded in Q2 2025.
- In the past 5 years, Myriad Genetics' Cash & Current Investments ranged from a high of $366.1 million in Q3 2021 and a low of $74.4 million during Q2 2025.
- In the last 3 years, Myriad Genetics' Cash & Current Investments had a median value of $99.9 million in 2024 and averaged $103.9 million.
- In the last 5 years, Myriad Genetics' Cash & Current Investments surged by 128.24% in 2021 and then tumbled by 70.57% in 2023.
- Over the past 5 years, Myriad Genetics' Cash & Current Investments (Quarterly) stood at $338.8 million in 2021, then slumped by 66.09% to $114.9 million in 2022, then grew by 22.63% to $140.9 million in 2023, then decreased by 27.32% to $102.4 million in 2024, then skyrocketed by 45.55% to $145.4 million in 2025.
- Its Cash & Current Investments was $145.4 million in Q3 2025, compared to $74.4 million in Q2 2025 and $91.8 million in Q1 2025.